Deregulation of the HOXA9/MEIS1 axis in acute leukemia

Cailin T. Collins, Jay Hess

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Purpose of review HOXA9 is a homeodomain transcription factor that plays an essential role in normal hematopoiesis and acute leukemia, in which its overexpression is strongly correlated with poor prognosis. The present review highlights recent advances in the understanding of genetic alterations leading to deregulation of HOXA9 and the downstream mechanisms of HOXA9-mediated transformation. Recent findings A variety of genetic alterations including MLL translocations, NUP98-fusions, NPM1 mutations, CDX deregulation, and MOZ-fusions lead to high-level HOXA9 expression in acute leukemias. The mechanisms resulting in HOXA9 overexpression are beginning to be defined and represent attractive therapeutic targets. Small molecules targeting MLL-fusion protein complex members, such as DOT1L and menin, have shown promising results in animal models, and a DOT1L inhibitor is currently being tested in clinical trials. Essential HOXA9 cofactors and collaborators are also being identified, including transcription factors PU.1 and C/EBPα, which are required for HOXA9-driven leukemia. HOXA9 targets including IGF1, CDX4, INK4A/INK4B/ARF, mir-21, and mir-196b and many others provide another avenue for potential drug development. Summary HOXA9 deregulation underlies a large subset of aggressive acute leukemias. Understanding the mechanisms regulating the expression and activity of HOXA9, along with its critical downstream targets, shows promise for the development of more selective and effective leukemia therapies.

Original languageEnglish (US)
Pages (from-to)354-361
Number of pages8
JournalCurrent Opinion in Hematology
Volume23
Issue number4
DOIs
StatePublished - Jul 1 2016

Fingerprint

Leukemia
Hematopoiesis
Transcription Factors
Animal Models
Clinical Trials
Mutation
Therapeutics
Pharmaceutical Preparations
Proteins

Keywords

  • acute myeloid leukemia
  • HOXA9
  • MEIS1
  • mixed lineage leukemia

ASJC Scopus subject areas

  • Hematology

Cite this

Deregulation of the HOXA9/MEIS1 axis in acute leukemia. / Collins, Cailin T.; Hess, Jay.

In: Current Opinion in Hematology, Vol. 23, No. 4, 01.07.2016, p. 354-361.

Research output: Contribution to journalReview article

Collins, Cailin T. ; Hess, Jay. / Deregulation of the HOXA9/MEIS1 axis in acute leukemia. In: Current Opinion in Hematology. 2016 ; Vol. 23, No. 4. pp. 354-361.
@article{96873277c3d04b0dadf28add55ec0f05,
title = "Deregulation of the HOXA9/MEIS1 axis in acute leukemia",
abstract = "Purpose of review HOXA9 is a homeodomain transcription factor that plays an essential role in normal hematopoiesis and acute leukemia, in which its overexpression is strongly correlated with poor prognosis. The present review highlights recent advances in the understanding of genetic alterations leading to deregulation of HOXA9 and the downstream mechanisms of HOXA9-mediated transformation. Recent findings A variety of genetic alterations including MLL translocations, NUP98-fusions, NPM1 mutations, CDX deregulation, and MOZ-fusions lead to high-level HOXA9 expression in acute leukemias. The mechanisms resulting in HOXA9 overexpression are beginning to be defined and represent attractive therapeutic targets. Small molecules targeting MLL-fusion protein complex members, such as DOT1L and menin, have shown promising results in animal models, and a DOT1L inhibitor is currently being tested in clinical trials. Essential HOXA9 cofactors and collaborators are also being identified, including transcription factors PU.1 and C/EBPα, which are required for HOXA9-driven leukemia. HOXA9 targets including IGF1, CDX4, INK4A/INK4B/ARF, mir-21, and mir-196b and many others provide another avenue for potential drug development. Summary HOXA9 deregulation underlies a large subset of aggressive acute leukemias. Understanding the mechanisms regulating the expression and activity of HOXA9, along with its critical downstream targets, shows promise for the development of more selective and effective leukemia therapies.",
keywords = "acute myeloid leukemia, HOXA9, MEIS1, mixed lineage leukemia",
author = "Collins, {Cailin T.} and Jay Hess",
year = "2016",
month = "7",
day = "1",
doi = "10.1097/MOH.0000000000000245",
language = "English (US)",
volume = "23",
pages = "354--361",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Deregulation of the HOXA9/MEIS1 axis in acute leukemia

AU - Collins, Cailin T.

AU - Hess, Jay

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Purpose of review HOXA9 is a homeodomain transcription factor that plays an essential role in normal hematopoiesis and acute leukemia, in which its overexpression is strongly correlated with poor prognosis. The present review highlights recent advances in the understanding of genetic alterations leading to deregulation of HOXA9 and the downstream mechanisms of HOXA9-mediated transformation. Recent findings A variety of genetic alterations including MLL translocations, NUP98-fusions, NPM1 mutations, CDX deregulation, and MOZ-fusions lead to high-level HOXA9 expression in acute leukemias. The mechanisms resulting in HOXA9 overexpression are beginning to be defined and represent attractive therapeutic targets. Small molecules targeting MLL-fusion protein complex members, such as DOT1L and menin, have shown promising results in animal models, and a DOT1L inhibitor is currently being tested in clinical trials. Essential HOXA9 cofactors and collaborators are also being identified, including transcription factors PU.1 and C/EBPα, which are required for HOXA9-driven leukemia. HOXA9 targets including IGF1, CDX4, INK4A/INK4B/ARF, mir-21, and mir-196b and many others provide another avenue for potential drug development. Summary HOXA9 deregulation underlies a large subset of aggressive acute leukemias. Understanding the mechanisms regulating the expression and activity of HOXA9, along with its critical downstream targets, shows promise for the development of more selective and effective leukemia therapies.

AB - Purpose of review HOXA9 is a homeodomain transcription factor that plays an essential role in normal hematopoiesis and acute leukemia, in which its overexpression is strongly correlated with poor prognosis. The present review highlights recent advances in the understanding of genetic alterations leading to deregulation of HOXA9 and the downstream mechanisms of HOXA9-mediated transformation. Recent findings A variety of genetic alterations including MLL translocations, NUP98-fusions, NPM1 mutations, CDX deregulation, and MOZ-fusions lead to high-level HOXA9 expression in acute leukemias. The mechanisms resulting in HOXA9 overexpression are beginning to be defined and represent attractive therapeutic targets. Small molecules targeting MLL-fusion protein complex members, such as DOT1L and menin, have shown promising results in animal models, and a DOT1L inhibitor is currently being tested in clinical trials. Essential HOXA9 cofactors and collaborators are also being identified, including transcription factors PU.1 and C/EBPα, which are required for HOXA9-driven leukemia. HOXA9 targets including IGF1, CDX4, INK4A/INK4B/ARF, mir-21, and mir-196b and many others provide another avenue for potential drug development. Summary HOXA9 deregulation underlies a large subset of aggressive acute leukemias. Understanding the mechanisms regulating the expression and activity of HOXA9, along with its critical downstream targets, shows promise for the development of more selective and effective leukemia therapies.

KW - acute myeloid leukemia

KW - HOXA9

KW - MEIS1

KW - mixed lineage leukemia

UR - http://www.scopus.com/inward/record.url?scp=84973443280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973443280&partnerID=8YFLogxK

U2 - 10.1097/MOH.0000000000000245

DO - 10.1097/MOH.0000000000000245

M3 - Review article

VL - 23

SP - 354

EP - 361

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 4

ER -